Discovery of AZD9750, an Orally Bioavailable Androgen Receptor Degrader for the Treatment of Prostate Cancer.
Saved in:
| Title: | Discovery of AZD9750, an Orally Bioavailable Androgen Receptor Degrader for the Treatment of Prostate Cancer. |
|---|---|
| Authors: | Scott JS; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Evans L; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Astles PC; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Argyrou A; Discovery Sciences, AstraZeneca, Cambridge CB2 0AA, U.K., Bagal SK; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Beattie D; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Braybrooke EL; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Cassar DJ; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Crafter C; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Diène C; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Fairley G; Oncology R&D, AstraZeneca, Macclesfield SK10 2NA, U.K., Fallan C; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Fraser G; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Galeano-Dalmau N; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Hammond TG; Safety Sciences, Clinical Pharmacology and Safety Sciences, AstraZeneca, Cambridge CB2 0AA, U.K., Hock AK; Discovery Sciences, AstraZeneca, Cambridge CB2 0AA, U.K., Jones T; Discovery Sciences, AstraZeneca, Cambridge CB2 0AA, U.K., Komen J; Safety Sciences, Clinical Pharmacology and Safety Sciences, AstraZeneca, Cambridge CB2 0AA, U.K., Lamont GM; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Michaloglou C; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Niedbala MJ; Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Ramos-Montoya A; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Rodrigo-Brenni MC; Safety Sciences, Clinical Pharmacology and Safety Sciences, AstraZeneca, Cambridge CB2 0AA, U.K., Packer MJ; Oncology R&D, AstraZeneca, Macclesfield SK10 2NA, U.K., Pearson S; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Pike A; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Schade M; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Shaw J; Discovery Sciences, AstraZeneca, Cambridge CB2 0AA, U.K., Shologu Z; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Steward O; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K. |
| Source: | Journal of medicinal chemistry [J Med Chem] 2026 Feb 12; Vol. 69 (3), pp. 3209-3232. Date of Electronic Publication: 2026 Jan 29. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-4804 (Electronic) Linking ISSN: 00222623 NLM ISO Abbreviation: J Med Chem Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
